Somatus Stock
Somatus partners with leading health plans, health systems, and nephrology and primary care groups to provide integrated care for patients with or at risk of developing kidney disease. Somatus' vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
Sign up for SecondMarket® to view the market and buy or sell Somatus Stock
Buy + SellSomatus Stock Price Chart
The below graph shows the estimated historical Somatus stock price as of last month, known as the Tape D® price. The Somatus Tape D® price is based on market activity, publicly-sourced valuation data, and other proprietary information. Create an account to see the current estimated Somatus price per share.
Somatus Funding
Sign up to gain insights into Somatus funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Date | Financing Round | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Jun 29, 2023 | Series F | 200.00M | ||
| Feb 28, 2022 | Series E | 341.69M | ||
| Jun 01, 2021 | Series D | 60.12M | ||
| May 27, 2020 | Series C | 64.00M | ||
| Mar 20, 2018 | Series B | 11.00M | ||
| Apr 20, 2017 | Series A | 5.00M |
See Somatus Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Somatus Stock Valuation + Share Prices
View real-time Tape D® data on Somatus stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket trading platform.
Get Started
Somatus Management Team
Director
Larry Renfro
Director
Thelma Duggin
Director
Garheng Kong
Director
Julian Harris
Chief Medical Officer
Joe Kimura
Director
Matt Downs
Director
Paul Weisbruch
Co-founder, CEO, Director
Ikenna Okezie
Chief Legal Officer
Alicia Palmer
Director
Dan Gebremedhin
Director
Amy Mulderry
Chief Commercial Officer
Chet Akiri
Co-founder, Chairman, Director
Anthony Welters
Somatus Major Investors
Deerfield Management Company
BlueCross BlueShield Venture Partners, L.P.
Inova Health System
Flare Capital Partners
Anthem, Inc.
GIC Special Investments Pte, Ltd.
Blue Ventures
RA Capital Management LLC
Optum Ventures
Wellington Management Company LLP
Fidelity Management & Research Company
Town Hall Ventures
Longitude Capital
Learn More About Somatus Stock
Buy Somatus Stock
01Somatus stock does not trade on public stock exchanges. Somatus stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Somatus stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Sell Somatus Stock
02Somatus Stock does not trade on public stock exchanges. In order to sell Somatus shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Somatus Stock Price
03Nasdaq Private Market estimates that Somatus price per share was $851.81 last month. This Somatus share value estimate (known as the Tape D™ price) is based on market activity, publicly-sourced valuation data, and other proprietary information. With Tape D premium for investors, you can get visibility into the Somatus share price today and the factors driving Somatus valuation estimates. Learn more about premium data here.
Read more about private company stock prices: Understanding the Bid-Ask Spread: How Buyers and Sellers Match on Price
Somatus Stock Ticker Symbol
04There is no ticker symbol for Somatus stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Criteria to Sell Somatus Stock
05Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Somatus stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in Somatus Stock
06Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Somatus stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Somatus Stock Settlement
07Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Somatus IPO
08Somatus is a private company and has not had an IPO. There is currently no Somatus IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to Somatus IPO.
Learn more about Tape D™ private company stock data for institutional investors on the on the Tape D™ Product Page.
Sign up for SecondMarket® to view the market and buy or sell Somatus Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
